Torrent Pharmaceuticals Ltd News

Torrent Pharma rises 5% on Q4 beat; brokerages divided on JBCP integration

Torrent Pharma's revenue from operations rose 42 per cent Y-o-Y to ₹4,197 crore in Q4FY26 from ₹2,959 crore in Q4FY25

Torrent Pharma Q4 profit falls 27% to ₹364 cr due to exceptional item outgo

Torrent Pharmaceuticals Ltd on Friday reported a 27 per cent decline in profit after tax to Rs 364 crore in the fourth quarter ended March 31, 2026, impacted by exceptional items outgo. The company had posted a net profit of Rs 498 crore in the corresponding period of the preceding fiscal, Torrent Pharmaceuticals said in a statement. Total revenue from operations in the fourth quarter of FY26 stood at Rs 4,197 crore as against Rs 2,959 crore in the year-ago period, it added. The company had exceptional items outgo of Rs 66 crore in the quarter, as per the regulatory filing. The board has recommended a final dividend of Rs 9 per equity share of a face value of Rs 5 each. The pharma company's India business revenue stood at Rs 2,215 crore, up 43 per cent, in the quarter, while the Brazil revenue came in at Rs 455 crore, up by 30 per cent. Revenue from the US business stood at Rs 396 crore, up 31 per cent year-on-year, Torrent Pharma said. For FY26, net profit increased to Rs 2,138

Torrent Pharma Q4 profit falls 21.9% on high expenses despite revenue boost

Torrent Pharma's Q4 profit dropped 22% as JB Pharma integration costs pushed up expenses, despite strong growth in semaglutide-led revenues

Why pharma stocks are emerging as safe bet amid global market turmoil

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Patent wins vs tariff risks: Analysts pick top pharma stocks to bet on

Pharma stocks have, so far, outperformed the markets in 2026. However, as risk around Trump tariffs resurface, analysts suggest shifting to domestic-focused companies. Here's the investment strategy.

Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount

Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country

Nifty Pharma index soars 7% thus far in February; nears 52-week high

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.

Pharma stocks in demand; Torrent hits new high; Natco up 6% on huge volumes

At 01:13 PM on Tuesday; Nifty Pharma index, the top gainer among sectoral indices, was up 0.2 per cent, as compared to 1.1 per cent decline in the Nifty 50.

Torrent Group forays into diagnostics with large national reference lab

Torrent Group has entered the diagnostics sector with a 100,000 sq ft national reference lab in Navi Mumbai, marking a long-term push into high-end, specialised testing amid industry consolidation

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

AU Bank, Torrent Pharma among 3 breakout stocks; strategy, key levels here

Om Mehra, tech analyst at SAMCO Securities highlights that Torrent Pharmaceuticals after a recent consolidation phase, has witnessed a strong breakout above ₹4,200 levels.

Torrent Pharma shares advance 6% as Q3 results meet D-St estimates

Torrent Pharma reported a 26.2 per cent jump in its net profit to ₹635 crore in Q3FY26. On a sequential basis, profit increased 7.4 per cent from ₹591 crore

Torrent Pharma Q3FY26 results: Profit rises 26%; revenue up 17.6%

Ahmedabad-based drugmaker reports Rs 635 crore Q3 profit on strong India, Brazil and US growth; revenues rise 17.6% to Rs 3,303 crore

Torrent Pharma Q3 result: Net profit up 26% at ₹635 cr, dividend declared

Torrent Pharma Q3 revenue from operations increased 17.7 per cent year-on-year (Y-o-Y) to ₹3,251 crore from ₹2,762 crore in Q3FY25

Nifty holds above key averages; 26,000 next? Levels to watch today

Nifty price prediction Feb 4: Key support at 25,500, resistance near 26,200. Also read Bank Nifty outlook, Nifty options data, and Chandan Taparia stock picks

India-EU FTA: Brokerages decode impact for markets, sectors, companies

In fiscal 2024-25 (FY25), India, according to HSBC, exported $76 billion worth of goods to the EU and bought $61 billion worth of goods from the EU

Torrent Pharma greenlights ₹12,500 crore fundraising plan via NCDs

Torrent Pharmaceuticals said the tenure of the instruments, along with the date of allotment and final maturity, will be determined at the time of issuance of NCDs

Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating